| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NA | sonidegib | odozmo | 200 mg | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Yes | 2015 | In Use | |||
| NA | Acalabrutinib | Calquence | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Yes | 2017 | In Use | |||
| Q2041 | Axicabtagene Ciloleucel | Yescarta | Up to 200 million | Immunotherapy | CAR-T | CD19 | No | 2017 | Jan 1, 2019 | In Use | ||
| NA | Chlorotrianisene | Anisene | 12 mg | Hormonal Therapy | Estrogen | Yes | 1992 | 1997 | In Use | |||
| NA | Leucovorin Calcium | Calcium leucovorin, Lederfoline, Leucosar, Leucovorin rescue, Wellcovorin | 15 mg | Ancillary Therapy | Chemoprotective | Antidote | Yes | 1952 | Jan 1, 1997 | In Use | ||
| J9295 | Necitumumab | Portrazza | 1 mg | Immunotherapy | Monoclonal Antibody | EGFR | No | 2015 | Jan 1, 2017 | In Use | ||
| J9145 | Daratumumab | Darzalex | 10 mg | Immunotherapy | Monoclonal Antibody | CD38 | No | 2015 | Jan 1, 2017 | In Use | ||
| NA | Nilotinib | Tasigna | 200 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2007 | In Use | |||
| J9022 | Atezolizumab | Tecentriq | 10mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2016 | Jan 1, 2018 | In Use | ||
| J9024 | Atezolizumab, hyaluronidase-tqjs | Tecentriq Hybreza | 5mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2024 | Mar 26, 2025 | In Use | ||
| Q5107 | Bevacizumab-awwb | Mvasi | 10mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2018 | Jan 1, 2019 | In Use | ||
| C9449 | Blinatumomab | Blincyto | 1 mcg | Immunotherapy | Monoclonal Antibody | CD3 (T cells) and CD19 (B cells) | No | 2014 | Apr 1, 2015 | In Use | ||
| J9092 | Cyclophosphamide | Cyclophosphamide | 2 g | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan 1, 1994 | In Use | ||
| J9181 | Etoposide | Toposar, Etopophos | 10 mg | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | No | 1983 | Jan 1, 1987 | In Use | ||
| S0179 | Megesterol | Megace | 20 mg | Hormonal Therapy | Progestin | Yes | 2002 | In Use | ||||
| Q5123 | Rituximab-arrx | Riabni | 10mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2021 | Jul 23, 2021 | In Use | ||
| J9056 | Bendamustine hydrochloride (Vivimusta) | Vivimusta | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2022 | Jul 11, 2023 | In Use | ||
| J9999 | Chemotherapy - non specific | Not otherwise classified, antineoplastic drugs | NA | Chemotherapy | No | In Use | ||||||
| S0172 | Chlorambucil | Leukeran | 2 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Yes | 1957 | Jan 1, 2002 | In Use | ||
| Vimseltinib | Romvimza | 14mg, 20mg, 30mg | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R | Yes | 2025 | In Use | ||||
| NA | Ruxolitinib | Jakafi | 20 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| NA | Belumosudil | Rezurock | 200mg | Chemotherapy | Rho Kinase Inhibitor | ROCK1, ROCK2 | Yes | 2021 | In Use | |||
| NA | Pirtobrutinib | Jaypirca | Multiple | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Yes | 2023 | In Use | |||
| J9360 | Vinblastine | Oncovin, Vincasar PFS | 1 mg | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | No | 1965 | Jan 1, 1986 | In Use | ||
| J9361 | Efbemalenograstim alfa-vuxw | Ryzneuta | 0.5mg | Immunotherapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | No | 2023 | Jun 10, 2024 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home